JP2020534289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534289A5 JP2020534289A5 JP2020515740A JP2020515740A JP2020534289A5 JP 2020534289 A5 JP2020534289 A5 JP 2020534289A5 JP 2020515740 A JP2020515740 A JP 2020515740A JP 2020515740 A JP2020515740 A JP 2020515740A JP 2020534289 A5 JP2020534289 A5 JP 2020534289A5
- Authority
- JP
- Japan
- Prior art keywords
- col
- para
- patent document
- abstract
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108010089429 PERK kinase Proteins 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023193160A JP2024023290A (ja) | 2017-09-14 | 2023-11-13 | がんの治療のための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558573P | 2017-09-14 | 2017-09-14 | |
| US62/558,573 | 2017-09-14 | ||
| PCT/US2018/051088 WO2019055786A1 (en) | 2017-09-14 | 2018-09-14 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023193160A Division JP2024023290A (ja) | 2017-09-14 | 2023-11-13 | がんの治療のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534289A JP2020534289A (ja) | 2020-11-26 |
| JP2020534289A5 true JP2020534289A5 (https=) | 2021-10-28 |
Family
ID=65724068
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515740A Pending JP2020534289A (ja) | 2017-09-14 | 2018-09-14 | がんの治療のための方法および組成物 |
| JP2023193160A Pending JP2024023290A (ja) | 2017-09-14 | 2023-11-13 | がんの治療のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023193160A Pending JP2024023290A (ja) | 2017-09-14 | 2023-11-13 | がんの治療のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200261414A1 (https=) |
| EP (2) | EP4176876A1 (https=) |
| JP (2) | JP2020534289A (https=) |
| ES (1) | ES2935729T3 (https=) |
| WO (1) | WO2019055786A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240084002A1 (en) * | 2020-12-07 | 2024-03-14 | Lankenau Institute For Medical Research | Methods and compositions utilizing ido1-dependent vascularizing cells for the treatment of pathological conditions involving neovascularization |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| CN117651548B (zh) | 2021-08-27 | 2026-03-03 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| CN119384281A (zh) | 2022-04-15 | 2025-01-28 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| CN119233822A (zh) | 2022-05-23 | 2024-12-31 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| KR20250160163A (ko) | 2023-02-27 | 2025-11-11 | 아센타위츠 파마슈티컬즈 리미티드 | 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법 |
| WO2025026214A1 (zh) | 2023-07-28 | 2025-02-06 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变或缺陷阴性癌症、肿瘤患者 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US7714139B2 (en) | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US7705022B2 (en) | 2005-10-27 | 2010-04-27 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080146624A1 (en) | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008058178A1 (en) | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CA2706378C (en) | 2007-11-20 | 2017-09-12 | Lankenau Institute For Medical Research | Disulfide chemotherapeutic agents and methods of use thereof |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| AU2013204313C1 (en) * | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| WO2016090174A1 (en) * | 2014-12-03 | 2016-06-09 | Auckland Uniservices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| EP4659747A2 (en) | 2015-07-24 | 2025-12-10 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| EP3359150A4 (en) * | 2015-10-05 | 2019-11-06 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS |
| US20190241573A1 (en) * | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
-
2018
- 2018-09-14 JP JP2020515740A patent/JP2020534289A/ja active Pending
- 2018-09-14 US US16/647,260 patent/US20200261414A1/en not_active Abandoned
- 2018-09-14 ES ES18856836T patent/ES2935729T3/es active Active
- 2018-09-14 WO PCT/US2018/051088 patent/WO2019055786A1/en not_active Ceased
- 2018-09-14 EP EP22199365.2A patent/EP4176876A1/en active Pending
- 2018-09-14 EP EP18856836.4A patent/EP3681498B1/en active Active
-
2023
- 2023-11-13 JP JP2023193160A patent/JP2024023290A/ja active Pending
- 2023-12-11 US US18/535,111 patent/US20240374566A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534289A5 (https=) | ||
| JP2024133475A5 (https=) | ||
| Fagundes et al. | Proton therapy for local-regionally advanced breast cancer maximizes cardiac sparing | |
| JP2006501147A5 (https=) | ||
| Lee et al. | Blocking cyclin-dependent kinase 4/6 during single dose versus fractionated radiation therapy leads to opposite effects on acute gastrointestinal toxicity in mice | |
| RU2017124371A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина | |
| Panwar et al. | Preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma: a changing trend towards preoperative radiotherapy in the UK | |
| JPWO2020022507A5 (https=) | ||
| Glicksman et al. | Concurrent platinum-based chemotherapy and hyperfractionated radiotherapy with late intensification in advanced head and neck cancer | |
| Naredi et al. | A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases | |
| Brunsvig et al. | Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years’ follow-up | |
| WO2013137433A1 (ja) | ３剤を組み合わせた新規な抗腫瘍剤 | |
| JP4956423B2 (ja) | 放射線治療増強剤 | |
| CA3224064A1 (en) | Capsaicin and trpv1 modulator compositions and methods of use thereof | |
| Bydder et al. | A controlled trial of misonidazole in the curative treatment of infiltrating bladder cancer | |
| Mayet | A practical approach to the patient receiving chemotherapy and anaesthesia | |
| Panchal et al. | Radiotherapy toxicity | |
| Riess et al. | Intralipid–the New Magic Bullet in Cardioprotection? | |
| Jin et al. | Anti-tumor effect of PDT using Photofrin in a mouse angiosarcoma model | |
| Gilbert et al. | Conditioning for acute myeloid leukemia: looking beyond intensity | |
| Damor et al. | Blue Nails in chronic myeloid leukemia-is it usual? | |
| Zaderenko et al. | Choosing options of surgical treatment for reccurent oropharyngeal cancer | |
| Mahmoud et al. | Metastatic renal cell carcinoma presenting as painful chewing successfully treated with combined nivolumab and sunitinib | |
| Beatriz | Adequate Selection of Oropharynx Carcinoma Treatment in the Elderly | |
| McNerney et al. | Acute left ventricular dysfunction following gemtuzumab ozogamicin in two children with AML |